Advanced search
Publication Cover
Clinical, Cosmetic and Investigational Dermatology Volume 15, 2022 - Issue
Submit an article Journal homepage
107
Views
0
CrossRef citations to date
0
Altmetric
CASE REPORT

Successful Treatment of a Patient with Pyoderma Gangrenosum, Plaque Psoriasis and Palmoplantar Pustulosis with Adalimumab

Yuqi ChuDepartment of Dermatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of ChinaView further author information
,
Taoming LiuDepartment of Dermatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of ChinaView further author information
,
Juan BaiDepartment of Dermatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of ChinaView further author information
,
Hong FangDepartment of Dermatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of ChinaView further author information
&
Jianjun QiaoDepartment of Dermatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-3386-297XView further author information
ORCID Icon
Pages 1991-1995 | Received 06 May 2022, Accepted 26 Jul 2022, Published online: 20 Sep 2022

References

  • Ashchyan HJ, Nelson CA, Stephen S, et al. Neutrophilic dermatoses: pyoderma gangrenosum and other bowel- and arthritis-associated neutrophilic dermatoses. J Am Acad Dermatol. 2018;79:1009–1022. doi:10.1016/j.jaad.2017.11.063
  • Maverakis E, Marzano AV, Le ST, et al. Pyoderma gangrenosum. Nat Rev Dis Primers. 2020;6(81). doi:10.1038/s41572-020-0213-x
  • Saternus R, Schwingel J, Muller CSL, Vogt T, Reichrath J. Ancient friends, revisited: systematic review and case report of pyoderma gangrenosum-associated autoinflammatory syndromes. J Transl Autoimmun. 2020;3:100071. doi:10.1016/j.jtauto.2020.100071
  • Satoh TK, Mellett M, Contassot E, French LE. Are neutrophilic dermatoses autoinflammatory disorders? Br J Dermatol. 2018;178:603–613. doi:10.1111/bjd.15105
  • Freitas E, Rodrigues MA, Torres T. Diagnosis, screening and treatment of Patients with Palmoplantar Pustulosis (PPP): a review of current practices and recommendations. Clin Cosmet Investig Dermatol. 2020;13:561–578. doi:10.2147/CCID.S240607
  • Ormerod AD, Thomas KS, Craig FE, et al. Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial. BMJ. 2015;350:h2958–h2958. doi:10.1136/bmj.h2958
  • Fischer-Stabauer M, Boehner A, Eyerich S, et al. Differential in situ expression of IL-17 in skin diseases. Eur J Dermatol. 2012;22:781–784. doi:10.1684/ejd.2012.1854
  • Ohtsuka M, Yamamoto T. Rare association of pyoderma gangrenosum and palmoplantar pustulosis: a case report and review of the previous works. J Dermatol. 2014;41:732–735. doi:10.1111/1346-8138.12543
  • Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323:1945–1960. doi:10.1001/jama.2020.4006
  • Yamasaki K, Yamanaka K, Zhao Y, et al. Adalimumab in Japanese patients with active ulcers of pyoderma gangrenosum: twenty-six-week Phase 3 open-label study. J Dermatol. 2020;47:1383–1390. doi:10.1111/1346-8138.15533
  • Pukar C, Sudha A, Punam P. Simultaneous occurrence of pyoderma gangrenosum and palmoplantar pustular psoriasis: is it an association or coincidental findings? Clin Case Rep. 2021;9(1):410–415. doi:10.1002/ccr3.3544
  • Noe MH, Wan MT, Mostaghimi A, et al. Evaluation of a case series of patients with palmoplantar pustulosis in the United States. JAMA Dermatol. 2022;158:68–72. doi:10.1001/jamadermatol.2021.4635
  • Kolios AG, Maul J-T, Meier B, et al. Canakinumab in adults with steroid-refractory pyoderma gangrenosum. Br J Dermatol. 2015;173:1216–1223. doi:10.1111/bjd.14037
  • Goldminz AM, Botto NC, Gottlieb AB. Severely recalcitrant pyoderma gangrenosum successfully treated with ustekinumab. J Am Acad Dermatol. 2012;67:e237–e238. doi:10.1016/j.jaad.2012.04.045
  • McPhie ML, Kirchhof MG. Pyoderma gangrenosum treated with secukinumab: a case report. SAGE Open Med Case Rep. 2020;8:2050313X20940430. doi:10.1177/2050313X20940430
  • John JM, Sinclair RD. Tildrakizumab for treatment of refractory pyoderma gangrenosum of the penis and polymyalgia rheumatica: killing two birds with one stone. Australas J Dermatol. 2020;61:170–171. doi:10.1111/ajd.13196
  • Brenner M, Ruzicka T, Plewig G, Thomas P, Herzer P. Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra. Br J Dermatol. 2009;161:1199–1201. doi:10.1111/j.1365-2133.2009.09404.x
  • Solovan C, Nicula Proca A, Ursoniu S. Pros and cons of biological therapy in psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):e74–e75. doi:10.1111/jdv.13735
  • Patel F, Fitzmaurice S, Duong C, et al. Effective strategies for the management of pyoderma gangrenosum: a comprehensive review. Acta Derm Venereol. 2015;95:525–531. doi:10.2340/00015555-2008
  • Martin DA, Towne JE, Kricorian G, et al. The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J Invest Dermatol. 2013;133:17–26. doi:10.1038/jid.2012.194

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.